Severity of regional myocardial dysfunction is not affected by cardiomyocyte apoptosis in non-ischemic heart failure

Tommaso Prescimone1, Vincenzo Lionetti, Chiara Caselli

  • 1Department of Cellular Biology and Physiopathology, University of Siena, Italy.

Pharmacological Research
|October 12, 2010
PubMed

Insights

Myocardial apoptosis does not follow a regional pattern in pacing-induced heart failure (HF). Biomarker expression suggests apoptosis activators and inhibitors are balanced, without impacting cardiomyocyte survival or regional dysfunction in non-ischemic HF.

Area of Science:

  • Cardiology
  • Cell Biology
  • Pathophysiology

Background:

  • The role of myocardial apoptosis in non-ischemic heart failure (HF) remains unclear.
  • Investigating regional patterns of apoptosis is crucial for understanding HF development.

Purpose of the Study:

  • To determine if myocardial apoptosis activation follows a regional pattern in pacing-induced HF.
  • To assess biomarkers of apoptosis and cell injury in specific left ventricular (LV) regions.

Main Methods:

  • Pacing-induced HF model in adult male minipigs.
  • Magnetic resonance imaging (MRI) to assess regional LV function and perfusion.
  • Analysis of LV tissue for apoptosis biomarkers (caspase-3, caspase-9, Bcl-2, Hsp72, TNF-α) and TUNEL assay.

Main Results:

  • Pacing induced significant LV dysfunction (reduced LV ejection fraction and LV end-systolic wall thickening at the pacing site).
  • Increased mRNA expression of caspase-3, Bcl-2, and Hsp72, and elevated TNF-α levels were observed at the pacing site.
  • The regional myocardial apoptotic index (TUNEL assay) remained unchanged in HF hearts.

Conclusions:

  • Myocardial apoptosis does not exhibit a regional pattern in this model of non-ischemic HF.
  • Apoptosis activators and inhibitors are expressed similarly, without affecting cardiomyocyte survival.
  • Regional myocardial dysfunction develops independently of significant changes in apoptosis magnitude.

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...